
    
      -  Subjects:lower respiratory tract infection patients

        -  Study design:randomized control study.The patients in study group will accept meropenem
           therapy with the regimen decided by a software developed from a PPK-PD model. The
           patients in control group will accept meropenem therapy with the regimen decided by
           attending physician.

        -  Primary endpoint: clinical successful rate of meropenem therapy. The clinical efficiency
           of meropenem therapy will be evaluated one week later from stop of meropenem therapy.

        -  Second endpoint: amount of used antibiotics and bacteriological successful rate.
    
  